Conclusions
PMR, REMISSION
Many inflammatory genes associated with JAK signaling are highly enriched in PBMCs from patients with PMR. Tofacitinib, a pan JAKi, effectively treated the PMR patients with clinical remission and a sharp decrease in CRP and ESR in this clinical trial study. Tofacitinib may effectively treat PMR patients. In the future, whether patients with PMR can be treated with tofacitinib alone should be carried out in the large phase randomized controlled trial.